These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 15632954)

  • 1. (99m)Tc-labeled murine ior C5 monoclonal antibody in colorectal carcinoma patients: pharmacokinetics, biodistribution, absorbed radiation doses to normal organs and tissues and tumor localization.
    Iznaga-Escobar N; Ramos-Suzarte M; Morales-Morales A; Torres-Arocha L; Rodríguez-Mesa N; Pérez-Rodriguez R
    Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):687-96. PubMed ID: 15632954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
    J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
    Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
    J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic efficacy and safety of 99mtc-labeled monoclonal antibody ior c5 in patients with colorectal and anal carcinomas: final report clinical trial phase I/II.
    Ramos-Suzarte M; Pintado AP; Mesa NR; Oliva JP; Iznaga-Escobar N; Aroche LT; Pimentel G; González J; Cordero M; Rodríguezi OT; Crombet RT; Pérez RR
    Cancer Biol Ther; 2007 Jan; 6(1):22-9. PubMed ID: 17224642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats.
    Iznaga Escobar N; Morales AM; Ducongé J; Torres IC; Fernández E; Gómez JA
    Nucl Med Biol; 1998 Jan; 25(1):17-23. PubMed ID: 9466357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation dosimetry of a 99mTc-labeled IgM murine antibody to CD15 antigens on human granulocytes.
    Mozley PD; Stubbs JB; Dresel SH; Barraclough ED; Smith T; Patel M; Finkelman C; Sparks RB; Thakur ML; Mathur A; Alavi A
    J Nucl Med; 1999 Apr; 40(4):625-30. PubMed ID: 10210221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pilot study with the monoclonal antibody IOR-C5 as a potential agent of radioimmunoscintigraphy in colorectal cancer].
    Oliva JP; Pimentel G; Borrón M; Peralta R; Ortiz R; Oliver B; Díaz N; Sánchez I; Vázquez AM; Baum RP
    Rev Esp Med Nucl; 2001 Jun; 20(4):282-8. PubMed ID: 11940415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
    Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
    J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI.
    Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G
    J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'.
    Macfarlane DJ; Smart RC; Tsui WW; Gerometta M; Eisenberg PR; Scott AM
    Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):648-56. PubMed ID: 16528525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.
    Lahorte CM; Bacher K; Burvenich I; Coene ED; Cuvelier C; De Potter C; Thierens H; Van de Wiele C; Dierckx RA; Slegers G
    J Nucl Med; 2004 Jun; 45(6):1065-73. PubMed ID: 15181142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
    Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel monoclonal antibody design for radioimmunotherapy.
    Forero A; Meredith RF; Khazaeli MB; Carpenter DM; Shen S; Thornton J; Schlom J; LoBuglio AF
    Cancer Biother Radiopharm; 2003 Oct; 18(5):751-9. PubMed ID: 14629823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.
    Goel A; Baranowska-Kortylewicz J; Hinrichs SH; Wisecarver J; Pavlinkova G; Augustine S; Colcher D; Booth BJ; Batra SK
    J Nucl Med; 2001 Oct; 42(10):1519-27. PubMed ID: 11585867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies.
    Van de Wiele C; Dumont F; Dierckx RA; Peers SH; Thornback JR; Slegers G; Thierens H
    J Nucl Med; 2001 Nov; 42(11):1722-7. PubMed ID: 11696645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
    Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
    Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies.
    Morales AA; Ducongé J; Alvarez-Ruiz D; Becquer-Viart ML; Núñez-Gandolff G; Fernández E; Caballero-Torres I; Iznaga-Escobar N
    Nucl Med Biol; 2000 Feb; 27(2):199-206. PubMed ID: 10773550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.